Atyr Pharma, Inc.

Ryan Andrew Adams

Leslie Ann Greene

Kristi Helen Piehl

Fei Hong

Jeffry Dean Watkins

Alain Philippe Vasserot

Ji Zhao

Wei Zhang

Kyle P Chiang

Alina He

Eva Rebecka Stephanie Armour

John D Mendlein

David J King

Ying Buechler

Chi-Fang Wu

Luke Burman

Yeeting Chong

Jeffrey M Greve

Zhiwen Xu

Jeffrey D Watkins

Rajesh Belani

Kenny D'Arigo

Eve Merriman

Eva R Armour

Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Compositions comprising anti-NRP2 antibodies

Therapeutic compositions comprising anti-NRP2 antibodies

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

Aminoacyl tRNA synthetases for modulating inflammation

Isolated aspartyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities

The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.

Aspartyl-tRNA synthetases

The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.

Aspartyl-tRNA synthetase-Fc conjugates

Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities

Amino acyl tRNA synthetases for modulating inflammation

Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.

Antibodies that bind tyrosyl-tRNA synthetases

Growing community of inventors

San Diego, CA, United States of America

Ryan Andrew Adams